4//SEC Filing
Claremount VII Associates, L.P. 4
Accession 0000950170-24-130257
CIK 0001568651other
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 4:33 PM ET
Size
14.8 KB
Accession
0000950170-24-130257
Insider Transaction Report
Form 4
Thrive Partners VII Growth GP, LLC
10% Owner
Transactions
- Purchase
Class A Common Stock
2024-11-20$16.97/sh+88,395$1,499,701→ 6,243,617 total(indirect: See footnote) - Purchase
Class A Common Stock
2024-11-21$16.86/sh+100,000$1,685,980→ 6,343,617 total(indirect: See footnote)
Thrive Partners VII GP, LLC
10% Owner
Transactions
- Purchase
Class A Common Stock
2024-11-21$16.86/sh+100,000$1,685,980→ 6,343,617 total(indirect: See footnote) - Purchase
Class A Common Stock
2024-11-20$16.97/sh+88,395$1,499,701→ 6,243,617 total(indirect: See footnote)
Claremount VII Associates, L.P.
10% Owner
Transactions
- Purchase
Class A Common Stock
2024-11-21$16.86/sh+100,000$1,685,980→ 6,343,617 total(indirect: See footnote) - Purchase
Class A Common Stock
2024-11-20$16.97/sh+88,395$1,499,701→ 6,243,617 total(indirect: See footnote)
Transactions
- Purchase
Class A Common Stock
2024-11-20$16.97/sh+88,395$1,499,701→ 6,243,617 total(indirect: See footnote) - Purchase
Class A Common Stock
2024-11-21$16.86/sh+100,000$1,685,980→ 6,343,617 total(indirect: See footnote)
Footnotes (3)
- [F1]Represents (i) 87,343 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,052 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.92 to $17.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,169,288 shares are held directly by Thrive VII Growth and 74,329 shares are held directly by Claremount VII.
- [F2]Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.
- [F3]Represents (i) 98,809 shares purchased by Thrive VII Growth and (ii) 1,191 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.60 to $17.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,268,097 shares are held directly by Thrive VII Growth and 75,520 shares are held directly by Claremount VII.
Documents
Issuer
Oscar Health, Inc.
CIK 0001568651
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001841808
Filing Metadata
- Form type
- 4
- Filed
- Nov 21, 7:00 PM ET
- Accepted
- Nov 22, 4:33 PM ET
- Size
- 14.8 KB